FibroBiologics (FBLG) Competitors

FibroBiologics logo
$0.84 -0.06 (-6.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.01 (-1.19%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FBLG vs. BYSI, CELU, RNAZ, NXTC, and ATOS

Should you buy FibroBiologics stock or one of its competitors? FibroBiologics's main competitors and comparable companies include BeyondSpring (BYSI), Celularity (CELU), TransCode Therapeutics (RNAZ), NextCure (NXTC), and Atossa Genetics (ATOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does FibroBiologics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

BeyondSpring's return on equity of 0.00% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
BeyondSpringN/A N/A -42.62%
FibroBiologics N/A -536.78%-225.12%

In the previous week, BeyondSpring and BeyondSpring both had 5 articles in the media. BeyondSpring's average media sentiment score of 0.94 beat FibroBiologics' score of 0.80 indicating that BeyondSpring is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeyondSpring
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
FibroBiologics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

FibroBiologics has a consensus price target of $73.00, suggesting a potential upside of 8,006.61%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than BeyondSpring.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

BeyondSpring has higher revenue and earnings than FibroBiologics. BeyondSpring is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeyondSpring$1.75M13.16-$1.01M-$0.12N/A
FibroBiologicsN/AN/A-$18.65M-$5.19N/A

BeyondSpring has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

40.3% of BeyondSpring shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 7.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BeyondSpring beats FibroBiologics on 8 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Celularity?

FibroBiologics (NASDAQ:FBLG) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

FibroBiologics has a net margin of 0.00% compared to Celularity's net margin of -246.65%. Celularity's return on equity of 0.00% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
FibroBiologicsN/A -536.78% -225.12%
Celularity -246.65%N/A -48.20%

In the previous week, FibroBiologics had 4 more articles in the media than Celularity. MarketBeat recorded 5 mentions for FibroBiologics and 1 mentions for Celularity. FibroBiologics' average media sentiment score of 0.80 beat Celularity's score of 0.60 indicating that FibroBiologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
FibroBiologics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celularity
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

FibroBiologics has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Celularity has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

FibroBiologics has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroBiologicsN/AN/A-$18.65M-$5.19N/A
Celularity$26.55M0.70-$91.72M-$1.69N/A

FibroBiologics currently has a consensus price target of $73.00, indicating a potential upside of 8,006.61%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts clearly believe FibroBiologics is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

19.0% of Celularity shares are held by institutional investors. 7.3% of FibroBiologics shares are held by insiders. Comparatively, 52.9% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

FibroBiologics beats Celularity on 8 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to TransCode Therapeutics?

FibroBiologics (NASDAQ:FBLG) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

FibroBiologics' return on equity of -536.78% beat TransCode Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
FibroBiologicsN/A -536.78% -225.12%
TransCode Therapeutics N/A -875.35%-37.46%

In the previous week, FibroBiologics had 5 more articles in the media than TransCode Therapeutics. MarketBeat recorded 5 mentions for FibroBiologics and 0 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.79 beat FibroBiologics' score of 0.80 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
FibroBiologics Positive
TransCode Therapeutics Very Positive

FibroBiologics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

FibroBiologics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroBiologicsN/AN/A-$18.65M-$5.19N/A
TransCode TherapeuticsN/AN/A-$34.66M-$52.37N/A

FibroBiologics presently has a consensus target price of $73.00, suggesting a potential upside of 8,006.61%. Given FibroBiologics' stronger consensus rating and higher possible upside, research analysts plainly believe FibroBiologics is more favorable than TransCode Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
TransCode Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

FibroBiologics beats TransCode Therapeutics on 8 of the 10 factors compared between the two stocks.

How does FibroBiologics compare to NextCure?

NextCure (NASDAQ:NXTC) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, FibroBiologics had 3 more articles in the media than NextCure. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for NextCure. FibroBiologics' average media sentiment score of 0.80 beat NextCure's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
FibroBiologics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NextCure presently has a consensus price target of $20.00, indicating a potential upside of 198.51%. FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 8,006.61%. Given FibroBiologics' higher probable upside, analysts plainly believe FibroBiologics is more favorable than NextCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

NextCure is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$6.77N/A
FibroBiologicsN/AN/A-$18.65M-$5.19N/A

NextCure has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

42.7% of NextCure shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 7.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NextCure's return on equity of -191.33% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -191.33% -125.95%
FibroBiologics N/A -536.78%-225.12%

Summary

FibroBiologics beats NextCure on 6 of the 11 factors compared between the two stocks.

How does FibroBiologics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

12.7% of Atossa Genetics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 7.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Atossa Genetics currently has a consensus target price of $20.33, indicating a potential upside of 970.18%. FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 8,006.61%. Given FibroBiologics' higher possible upside, analysts plainly believe FibroBiologics is more favorable than Atossa Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
FibroBiologics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Atossa Genetics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.11N/A
FibroBiologicsN/AN/A-$18.65M-$5.19N/A

Atossa Genetics' return on equity of -117.07% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -117.07% -96.08%
FibroBiologics N/A -536.78%-225.12%

In the previous week, FibroBiologics had 5 more articles in the media than Atossa Genetics. MarketBeat recorded 5 mentions for FibroBiologics and 0 mentions for Atossa Genetics. Atossa Genetics' average media sentiment score of 1.20 beat FibroBiologics' score of 0.80 indicating that Atossa Genetics is being referred to more favorably in the media.

Company Overall Sentiment
Atossa Genetics Positive
FibroBiologics Positive

Atossa Genetics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

Summary

Atossa Genetics beats FibroBiologics on 8 of the 12 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBLG vs. The Competition

MetricFibroBiologicsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.59M$3.97B$7.59B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-0.1624.6233.5830.13
Price / SalesN/A15.448.255.59
Price / CashN/A22.9521.0121.90
Price / Book0.454.164.443.72
Net Income-$18.65M-$24.10M$3.50B$393.88M
7 Day Performance-15.65%-8.44%-6.53%-6.07%
1 Month Performance-13.49%-6.54%-4.93%-7.38%
1 Year Performance-87.28%-6.71%-1.73%-7.48%

FibroBiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBLG
FibroBiologics
1.9095 of 5 stars
$0.84
-6.7%
$73.00
+8,590.5%
-86.6%$5.59MN/AN/A15
BYSI
BeyondSpring
0.2336 of 5 stars
$0.58
-6.0%
N/A-72.7%$23.84M$1.75MN/A44
CELU
Celularity
0.1275 of 5 stars
$0.71
-6.4%
N/A-62.4%$23.07M$26.55MN/A115
RNAZ
TransCode Therapeutics
0.913 of 5 stars
$1.35
-12.3%
N/A-85.0%$22.86MN/AN/A12
NXTC
NextCure
2.8689 of 5 stars
$5.98
-4.6%
$20.00
+234.4%
-34.0%$21.59MN/AN/A40

Related Companies and Tools


This page (NASDAQ:FBLG) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners